Daiichi Sankyo Gains FDA Approval for Datroway in Unresectable or Metastatic TNBC

Daiichi Sankyo's antibody-drug conjugate Datroway (datopotamab deruxtecan-dlnk) cleared FDA approval on May 22, 2026, adding a commercially authorized ADC to a therapeutic class whose complex biologics manufacturing and multi-agency regulatory coordination are already stress-testing quality systems across the industry. For plant heads and QA directors managing ADC production, the approval signals an expanding commercial pipeline that demands validated conjugation processes, robust sterility assurance, and supply chains capable of supporting concurrent international launches.

Approval was based on the TROPION-Breast02 trial (NCT05374512), a 644-patient, open-label, randomized study in adults with unresectable or metastatic triple-negative breast cancer who had not received prior systemic therapy for metastatic disease and were not candidates for PD-1/PD-L1 inhibitor therapy. Datopotamab deruxtecan-dlnk demonstrated a median progression-free survival of 10.8 months versus 5.6 months for investigator-choice chemotherapy (HR 0.57; p<0.0001), with a confirmed overall response rate of 64% against 30%. Median overall survival reached 23.7 months compared with 18.7 months in the chemotherapy arm (HR 0.79; p=0.0290).

The prescribing information carries warnings for interstitial lung disease and pneumonitis, ocular adverse reactions, stomatitis/oral mucositis, and embryo-fetal toxicity. For pharmacovigilance and post-market surveillance teams, these labelled risks translate directly into signal-monitoring obligations and adverse-event reporting protocols under 21 CFR Part 314 and applicable ICH E2E guidance.

The review was conducted under Project Orbis, the FDA Oncology Center of Excellence's framework for concurrent multinational oncology submissions. Participating agencies include Australia's TGA, Brazil's ANVISA, Health Canada, Singapore's HSA, and Switzerland's Swissmedic, with reviews still ongoing at several of those bodies. Regulatory affairs leads preparing dossiers for these markets should note that Project Orbis timelines do not guarantee synchronised approvals; manufacturing site readiness and CMC package alignment across jurisdictions remain the critical path items for global launch execution.

The application received priority review designation and used the FDA's voluntary Assessment Aid submission tool to facilitate agency evaluation. The recommended dose is 6 mg/kg administered as an intravenous infusion every 21 days, with a 540 mg cap for patients at or above 90 kg.

With Project Orbis partner decisions still pending, the completeness of Daiichi Sankyo's CMC submissions to TGA, ANVISA, Health Canada, HSA, and Swissmedic will determine how closely international approvals trail the US clearance.

Source: FDA Drugs@FDA / What's New: Drugs RSS Feed, May 22, 2026.